Vivek Subbiah: Comments on the ESMO Presidential Symposium Precision Oncology trials and DRUP-like trials
Vivek Subbiah shared a post on LinkedIn by ESMO adding:
“Hot off the press Read my comments on the ESMO Presidential Symposium Precision Oncology trials and DRUP-like trials presented at ESMO24
ESMO24: Drug rediscovery trials facilitate access to Precision Oncology and highlight the importance of integrating comprehensive Genomic Profiling into clinical practice across a broad range of tumour types ESMO Daily Reporter.”
Quoting ESMO’s post below:
“Evidence for the feasibility, early efficacy and safety of incorporating comprehensive Genomic Profiling into clinical practice to provide personalised treatments based on Drug Rediscovery Protocol-like Clinical Trials (DLCTs) was presented at ESMO24. DLCTs explore the effects of biomarker-driven treatments outside their approved indication(s) across a broad range of tumour types, thus enabling the study of Precision Oncology in large patient numbers, according to Vivek Subbiah.
Source: Vivek Subbiah/LinkedIn and ESMO/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023